Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 10066 participants.
Also called NCT01327846
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 10,066 participants
- Sponsor
- Registry
-
NCT01327846 -
2010-022970-14
-
- Other papers using this trial's data
- Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes
- Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
- Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
- Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial
- Effects of Interleukin-1β Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk: A Secondary Analysis of CANTOS
- Effects of Interleukin-1β Inhibition on Incident Anemia: Exploratory Analyses From a Randomized Trial
- Effects of Interleukin-1β Inhibition on Incident Hip and Knee Replacement : Exploratory Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial
- Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial
- Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease
- Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
- Relationship of Interleukin-1β Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial
- Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis
- TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Guatemala, Hungary, Iceland, India, Italy, Japan, Latvia, Lithuania, Mexico, Netherlands, Norway, Peru, Poland, Puerto Rico, Romania, Russia, Serbia, Slovakia, Slovenia, South Africa, South Korea, Sweden, Taiwan, Türkiye, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01327846. Randomized; triple masking; primary purpose treatment. Start 2011-04-11 (actual); primary completion 2017-03-28 (actual). Results posted on 2020-01-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
- Acronym
- CANTOS
- Condition
- Atherosclerosis
- Intervention (Drug)
- Canakinumab
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Standard of care
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01327846- Content hash
398f36d8870b264b0dae4afe23698ece5afd02016a5bc29905fc351ac4990461